These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

482 related items for PubMed ID: 33316771

  • 1. Prognostic and predictive roles of DNA mismatch repair status in colon cancer patients treated with oxaliplatin-based chemotherapy: a retrospective study.
    Qin Q, Zhou AP, Yang L, Xu C, Sun YK, Zhang W, Wang JW, Zhong DS.
    J Physiol Pharmacol; 2020 Aug; 71(4):. PubMed ID: 33316771
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Defective Mismatch Repair Status was not Associated with DFS and OS in Stage II Colon Cancer Treated with Adjuvant Chemotherapy.
    Kim JE, Hong YS, Kim HJ, Kim KP, Lee JL, Park SJ, Lim SB, Park IJ, Kim CW, Yoon YS, Yu CS, Kim JC, Hoon KJ, Kim TW.
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S630-7. PubMed ID: 26271397
    [Abstract] [Full Text] [Related]

  • 4. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
    André T, de Gramont A, Vernerey D, Chibaudel B, Bonnetain F, Tijeras-Raballand A, Scriva A, Hickish T, Tabernero J, Van Laethem JL, Banzi M, Maartense E, Shmueli E, Carlsson GU, Scheithauer W, Papamichael D, Möehler M, Landolfi S, Demetter P, Colote S, Tournigand C, Louvet C, Duval A, Fléjou JF, de Gramont A.
    J Clin Oncol; 2015 Dec 10; 33(35):4176-87. PubMed ID: 26527776
    [Abstract] [Full Text] [Related]

  • 5. Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials.
    Zaanan A, Shi Q, Taieb J, Alberts SR, Meyers JP, Smyrk TC, Julie C, Zawadi A, Tabernero J, Mini E, Goldberg RM, Folprecht G, Van Laethem JL, Le Malicot K, Sargent DJ, Laurent-Puig P, Sinicrope FA.
    JAMA Oncol; 2018 Mar 01; 4(3):379-383. PubMed ID: 28983557
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.
    Sinicrope FA, Mahoney MR, Smyrk TC, Thibodeau SN, Warren RS, Bertagnolli MM, Nelson GD, Goldberg RM, Sargent DJ, Alberts SR.
    J Clin Oncol; 2013 Oct 10; 31(29):3664-72. PubMed ID: 24019539
    [Abstract] [Full Text] [Related]

  • 8. [Correlations between DNA mismatch repair (MMR) and prognosis and prediction of treatment efficacy in stage II/II colon cancer].
    Qin Q, Ying J, Lyu N, Guo L, Zhi W, Zhou A, Wang J.
    Zhonghua Zhong Liu Za Zhi; 2014 Nov 10; 36(11):844-8. PubMed ID: 25620482
    [Abstract] [Full Text] [Related]

  • 9. The effects of oxaliplatin-based adjuvant chemotherapy in high-risk stage II colon cancer with mismatch repair-deficient: a retrospective study.
    Liao L, Tang J, Hong Z, Jiang W, Li Y, Kong L, Han K, Hou Z, Zhang C, Zhou C, Zhang L, Sui Q, Xiao B, Mei W, Yu J, Yang W, Pan Z, Ding PR.
    BMC Cancer; 2024 Feb 02; 24(1):164. PubMed ID: 38302968
    [Abstract] [Full Text] [Related]

  • 10. Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy.
    Zaanan A, Fléjou JF, Emile JF, Des GG, Cuilliere-Dartigues P, Malka D, Lecaille C, Validire P, Louvet C, Rougier P, de Gramont A, Bonnetain F, Praz F, Taïeb J.
    Clin Cancer Res; 2011 Dec 01; 17(23):7470-8. PubMed ID: 21998335
    [Abstract] [Full Text] [Related]

  • 11. Mismatch repair phenotype determines the implications of tumor grade and CDX2 expression in stage II-III colon cancer.
    Hestetun KE, Aasebø K, Rosenlund NB, Müller Y, Dahl O, Myklebust MP.
    Mod Pathol; 2021 Jan 01; 34(1):161-170. PubMed ID: 32737450
    [Abstract] [Full Text] [Related]

  • 12. Correlation between mismatch repair and survival of patients with gastric cancer after 5-FU-based adjuvant chemotherapy.
    Zhao F, Li E, Shen G, Dong Q, Ren D, Wang M, Zhao Y, Liu Z, Ma J, Xie Q, Liu Z, Li Z, Gao L, Zhao J.
    J Gastroenterol; 2023 Jul 01; 58(7):622-632. PubMed ID: 37036516
    [Abstract] [Full Text] [Related]

  • 13. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.
    Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, French AJ, Kabat B, Foster NR, Torri V, Ribic C, Grothey A, Moore M, Zaniboni A, Seitz JF, Sinicrope F, Gallinger S.
    J Clin Oncol; 2010 Jul 10; 28(20):3219-26. PubMed ID: 20498393
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study.
    Tougeron D, Mouillet G, Trouilloud I, Lecomte T, Coriat R, Aparicio T, Des Guetz G, Lécaille C, Artru P, Sickersen G, Cauchin E, Sefrioui D, Boussaha T, Ferru A, Matysiak-Budnik T, Silvain C, Karayan-Tapon L, Pagès JC, Vernerey D, Bonnetain F, Michel P, Taïeb J, Zaanan A.
    J Natl Cancer Inst; 2016 Jul 10; 108(7):. PubMed ID: 26839356
    [Abstract] [Full Text] [Related]

  • 15. Association of obesity with DNA mismatch repair status and clinical outcome in patients with stage II or III colon carcinoma participating in NCCTG and NSABP adjuvant chemotherapy trials.
    Sinicrope FA, Foster NR, Yoon HH, Smyrk TC, Kim GP, Allegra CJ, Yothers G, Nikcevich DA, Sargent DJ.
    J Clin Oncol; 2012 Feb 01; 30(4):406-12. PubMed ID: 22203756
    [Abstract] [Full Text] [Related]

  • 16. Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
    Taieb J, Shi Q, Pederson L, Alberts S, Wolmark N, Van Cutsem E, de Gramont A, Kerr R, Grothey A, Lonardi S, Yoshino T, Yothers G, Sinicrope FA, Zaanan A, André T.
    Ann Oncol; 2019 Sep 01; 30(9):1466-1471. PubMed ID: 31268130
    [Abstract] [Full Text] [Related]

  • 17. Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy.
    Gallois C, Taieb J, Le Corre D, Le Malicot K, Tabernero J, Mulot C, Seitz JF, Aparicio T, Folprecht G, Lepage C, Mini E, Van Laethem JL, Emile JF, Laurent-Puig P, PETACC8 investigators.
    Clin Cancer Res; 2018 Oct 01; 24(19):4745-4753. PubMed ID: 29921730
    [Abstract] [Full Text] [Related]

  • 18. Effects of deficient mismatch repair on the prognosis of patients with stage II and stage III colon cancer during different postoperative periods.
    Zhang C, Zhan Y, Ni K, Liu Z, Xin R, Han Q, Li G, Ping H, Liu Y, Zhao X, Wang W, Yan S, Sun J, Zhang Q, Wang G, Zhang Z, Zhang X, Hu X.
    BMC Cancer; 2022 Nov 10; 22(1):1156. PubMed ID: 36352365
    [Abstract] [Full Text] [Related]

  • 19. [Analysis of the relationship of DNA mismatch repair with clinicopathologic features and prognosis of colon cancer].
    Qin Q, Ying J, Lyu N, Guo L, Zhi W, Zhou A, Wang J.
    Zhonghua Zhong Liu Za Zhi; 2015 Aug 10; 37(8):591-6. PubMed ID: 26714599
    [Abstract] [Full Text] [Related]

  • 20. Mitochondrial DNA Copy Number as a Biomarker for Guiding Adjuvant Chemotherapy in Stages II and III Colorectal Cancer Patients with Mismatch Repair Deficiency: Seeking Benefits and Avoiding Harms.
    Chen M, Deng S, Cao Y, Wang J, Zou F, Gu J, Mao F, Xue Y, Jiang Z, Cheng D, Huang N, Huang L, Cai K.
    Ann Surg Oncol; 2024 Sep 10; 31(9):6320-6330. PubMed ID: 38985229
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.